替吉奥联合白蛋白紫杉醇在一线治疗晚期胰腺癌中的研究进展
摘要
胰腺癌患者生存期的最佳选择，但只有15% ～ 20%的胰腺癌患者能接受手术治疗。目前晚期胰腺癌患者的首选治
疗方式是以吉西他滨为基础的化疗，但仅使晚期胰腺癌患者的平均生存期延长为5.5 ～ 7个月，疗效有限，且不良反
应较大。目前，该方案已被部分指南推荐用于体能状态较差的老年患者。近几年，多项研究证实白蛋白结合型紫杉
醇联合替吉奥治疗晚期胰腺癌可以提高患者的PFS和OS（分别为6.2个月和13.6个月）。疗过程中最常出现的不良反
应较少，为晚期胰腺癌患者的治疗带来了新希望。本文综述了近年来替吉奥联合白蛋白紫杉醇在晚期胰腺癌治疗中
的研究进展。
关键词
全文:
PDF参考
[1]Thibodeau S, Voutsadakis I A. FOLFIRINOX
chemotherapy in metastatic pancreatic cancer: a systematic
review and meta-analysis of retrospective and phase II
studies[J]. Journal of clinical medicine, 2018, 7(1): 7.
[2]Von Hoff D D, Ervin T, Arena F P, et al. Increased
survival in pancreatic cancer with nab-paclitaxel plus
gemcitabine[J]. New England journal of medicine, 2013,
369(18): 1691-1703.
[3]Nipp R, Tramontano A C, Kong C Y, et al. Disparities in
cancer outcomes across age, sex, and race/ethnicity among patients
with pancreatic cancer[J]. Cancer medicine, 2018, 7(2): 525-535.
[4]陆滢滢，吉冬丽，殷荣华，等.白蛋白结合型紫
杉醇联合吉西他滨一线治疗晚期胰腺癌的疗效观察[J].临
床和实验医学杂志，2019，18（24）：2649-2652.
[5]王娅玲，丁宁欣，李文雄.白蛋白结合型紫杉醇联合吉西他滨与吉西他滨比较治疗晚期胰腺癌的卫生经济学
评价[J].中国循证医学杂志，2019，19（09）：1101-1105.
[6]张娜，王锦毓，应杰儿.吉西他滨/白蛋白结合型
紫杉醇与FOLFIRINOX用于晚期胰腺癌姑息性一线治
疗：倾向评分分析解读[J].肿瘤学杂志，2022，28（02）：
155-161.
[7]Ueno H, Ioka T, Ikeda M, et al. Randomized phase
III study of gemcitabine plus S-1, S-1 alone, or gemcitabine
alone in patients with locally advanced and metastatic
pancreatic cancer in Japan and Taiwan: GEST study[J].
Journal of Clinical Oncology, 2013, 31(13): 1640-1648.
[8]吴莉，郑桐森.白蛋白结合型紫杉醇联合替吉奥
治疗晚期胰腺癌的研究进展[J].现代肿瘤医学，2022，30
（09）：1706-1709.
[9]韩倩倩，鲁培，秦艳茹，等.白蛋白结合型紫杉
醇联合替吉奥治疗老年晚期胰腺癌的效果及安全性观察
[J].河南医学研究，2018，27（09）：1561-1563.
[10]Shirasaka T, Shimamato Y, Ohshimo H, et al.
Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators[J]. Anti-cancer drugs, 1996, 7(5): 548-557.
[11]Tatsumi K, FUKUSHIMA M, SHIRASAKA T,
et al. Inhibitory effects of pyrimidine, barbituric acid and
pyridine derivatives on 5-fluorouracil degradation in rat liver
extracts[J]. Japanese Journal of Cancer Research GANN,
1987, 78(7): 748-755.
[12]Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil
versus combination of irinotecan plus cisplatin versus S-1 in
metastatic gastric cancer: a randomised phase 3 study[J]. The
lancet oncology, 2009, 10(11): 1063-1069.
[13]Gelderblom H, Verweij J, Nooter K, et al.
Cremophor EL:the drawbacks and advantages of vehicle
selection for drug formulation[J]. Eur J Cancer, 2001,
37(13):1590-1598.
[14]Ford HE, Marshall A, Bridgewater JA, et al.
Docetaxel versus active symptom control for refractory
oesophagogastric adenocarcinoma(COUGAR-02):an openlabel, phase3 randomised controlled trial[J]. Lancet Oncol,
2014, 15(1):78-86.
[15]杨科，李峻岭，杜斌，等.白蛋白结合型紫杉醇
二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索
性临床研究[J].中国临床药理学与治疗学，2019，24（11）：
1281-1286.
[16]王娅玲，丁宁欣，李文雄.白蛋白结合型紫杉醇
联合吉西他滨与吉西他滨比较治疗晚期胰腺癌的卫生经济
学评价[J].中国循证医学杂志，2019，19（9）：1101-1105.
[17]崔瀚之，杜丽文，樊梦娇，等.晚期胰腺癌治疗现
状与进展[J].解放军医学院学报，2020，41（9）：926-929.
[18]Sofia, Palacio, Peter, et al. The nab -paclitaxel/
gemcitabine regimen for patients with refractory advanced
pancreatic adenocarcinoma[J]. Journal of Gastrointestinal
Oncology, 2018,9(1): 135-139.
[19]Li J A, Xu X F, Han X, et al. Nab-paclitaxel plus
S-1 shows increased antitumor activity in patient-derived
pancreatic cancer xenograft mouse models[J]. Pancreas, 2016,
45(3): 425-433.
[20]Suenaga M, Yamada S, Fujii T, et al. S‐1 plus
nab‐paclitaxel is a promising regimen for pancreatic cancer
in a preclinical model[J]. Journal of Surgical Oncology, 2016,
113(4): 413-419.
[21]Jin M, Liu H L, Xue J, et al. Nab-paclitaxel plus
S-1 versus nab-paclitaxel plus gemcitabine in patients with
advanced pancreatic cancer: a multicenter, randomized, phase
II study[J]. The Oncologist, 2024, 29(10): e1406-e1418.
[22]Li J A, Xu X F, Han X, et al. Nab-paclitaxel plus
S-1 shows increased antitumor activity in patient-derived
pancreatic cancer xenograft mouse models[J]. Pancreas, 2016,
45(3): 425-433.
[23]Uesaka K, Boku N, Fukutomi A, et al. Adjuvant
chemotherapy of S-1 versus gemcitabine for resected
pancreatic cancer: a phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01)[J]. The Lancet, 2016,
388(10041): 248-257.
[24]ZONG Y,YUAN J,PENG Z,et al. Nab - paclitaxel
plus S - 1 versus nab - paclitaxel plus gemcitabine as first -
line chemotherapy in patients with advanced pancreatic ductal
adenocarcinoma:a randomized study [J]. J Cancer Res Clin
Oncol,2021,147(5): 1529 - 1536.
[25]Shi Y, Yan H, Han Q, et al. Nab-paclitaxel plus S-1
as first-line treatment in patients with advanced pancreatic
adenocarcinoma[J]. 2017.
[26]Chen Y, Gu J, Yin M, et al. Safety and efficacy of S1
monotherapy or combined with nab-paclitaxel in advanced
elderly pancreatic cancer patients: A meta-analysis[J].
Medicine, 2021, 100(25): e26342.
Refbacks
- 当前没有refback。
